Shanshan Jiang1,2,3, Tianyu Zou2, Charles G Eberhart4, Maria A V Villalobos4, Hye-Young Heo1, Yi Zhang1, Yu Wang5, Xianlong Wang2, Hao Yu2, Yongxing Du2, Peter C M van Zijl1,6, Zhibo Wen2, Jinyuan Zhou1,6. 1. Division of MR Research, Department of Radiology, Johns Hopkins University, Baltimore, Maryland, USA. 2. Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. 3. Department of Radiology, Futian Traditional Chinese Medicine Hospital, Shenzhen, Guangdong, China. 4. Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA. 5. Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. 6. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Abstract
PURPOSE: To assess the amide proton transfer-weighted (APTw) MRI features of isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant grade II gliomas and to test the hypothesis that the APTw signal is a surrogate imaging marker for identifying IDH mutation status preoperatively. METHODS: Twenty-seven patients with pathologically confirmed low-grade glioma, who were previously scanned at 3T, were retrospectively analyzed. The Mann-Whitney test was used to evaluate relationships between APTw intensities for IDH-mutant and IDH-wildtype groups, and receiver operator characteristic (ROC) analysis was used to assess the diagnostic performance of APTw. RESULTS: Based on histopathology and molecular analysis, seven cases were diagnosed as IDH-wildtype grade II gliomas and 20 cases as IDH-mutant grade II gliomas. The maximum and minimum APTw values, based on multiple regions of interest, as well as the whole-tumor histogram-based mean and 50th percentile APTw values, were significantly higher in the IDH-wildtype gliomas than in the IDH-mutant groups. This corresponded to the areas under the ROC curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status. CONCLUSION: IDH-wildtype lesions typically were associated with relatively high APTw signal intensities as compared with IDH-mutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade II gliomas. Magn Reson Med 78:1100-1109, 2017.
PURPOSE: To assess the amide proton transfer-weighted (APTw) MRI features of isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant grade II gliomas and to test the hypothesis that the APTw signal is a surrogate imaging marker for identifying IDH mutation status preoperatively. METHODS: Twenty-seven patients with pathologically confirmed low-grade glioma, who were previously scanned at 3T, were retrospectively analyzed. The Mann-Whitney test was used to evaluate relationships between APTw intensities for IDH-mutant and IDH-wildtype groups, and receiver operator characteristic (ROC) analysis was used to assess the diagnostic performance of APTw. RESULTS: Based on histopathology and molecular analysis, seven cases were diagnosed as IDH-wildtype grade II gliomas and 20 cases as IDH-mutant grade II gliomas. The maximum and minimum APTw values, based on multiple regions of interest, as well as the whole-tumor histogram-based mean and 50th percentile APTw values, were significantly higher in the IDH-wildtype gliomas than in the IDH-mutant groups. This corresponded to the areas under the ROC curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status. CONCLUSION:IDH-wildtype lesions typically were associated with relatively high APTw signal intensities as compared with IDH-mutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade II gliomas. Magn Reson Med 78:1100-1109, 2017.
Authors: K Yamashita; A Hiwatashi; O Togao; K Kikuchi; R Hatae; K Yoshimoto; M Mizoguchi; S O Suzuki; T Yoshiura; H Honda Journal: AJNR Am J Neuroradiol Date: 2015-09-24 Impact factor: 3.825
Authors: Luke Macyszyn; Hamed Akbari; Jared M Pisapia; Xiao Da; Mark Attiah; Vadim Pigrish; Yingtao Bi; Sharmistha Pal; Ramana V Davuluri; Laura Roccograndi; Nadia Dahmane; Maria Martinez-Lage; George Biros; Ronald L Wolf; Michel Bilello; Donald M O'Rourke; Christos Davatzikos Journal: Neuro Oncol Date: 2015-07-16 Impact factor: 12.300
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Koichi Ichimura; Danita M Pearson; Sylvia Kocialkowski; L Magnus Bäcklund; Raymond Chan; David T W Jones; V Peter Collins Journal: Neuro Oncol Date: 2009-05-12 Impact factor: 12.300
Authors: Daniel Paech; Constantin Dreher; Sebastian Regnery; Jan-Eric Meissner; Steffen Goerke; Johannes Windschuh; Johanna Oberhollenzer; Miriam Schultheiss; Katerina Deike-Hofmann; Sebastian Bickelhaupt; Alexander Radbruch; Moritz Zaiss; Andreas Unterberg; Wolfgang Wick; Martin Bendszus; Peter Bachert; Mark E Ladd; Heinz-Peter Schlemmer Journal: Eur Radiol Date: 2019-02-26 Impact factor: 5.315
Authors: Y-L Wang; J Yao; A Chakhoyan; C Raymond; N Salamon; L M Liau; P L Nghiemphu; A Lai; W B Pope; N Nguyen; M Ji; T F Cloughesy; B M Ellingson Journal: AJNR Am J Neuroradiol Date: 2019-05-16 Impact factor: 3.825